Anaphylaxis Treatment Market: The Growth Of Anaphylaxis Treatment Market And Introduction To Auto-Injectors In The Global Market

Anaphylaxis Treatment Market   Anaphylaxis is a serious, allergic reaction that is to be treated immediately. Anaphylaxis is a life-threatening reaction with cardiovascular, respiratory, gastrointestinal, or cutaneous manifestations resulting from exposure to an offending agent, usually insect sting, food, physical factor, or medication. It is typical causes more than one…

Anaphylaxis Treatment Market

 

Anaphylaxis is a serious, allergic reaction that is to be treated immediately. Anaphylaxis is a life-threatening reaction with cardiovascular, respiratory, gastrointestinal, or cutaneous manifestations resulting from exposure to an offending agent, usually insect sting, food, physical factor, or medication. It is typical causes more than one of the symptoms such as throat or tongue swelling, itchy rash, vomiting, shortness of breath, light-headedness, and low blood pressure.

Global Anaphylaxis treatment market is driven by the increase in the incidence of anaphylaxis around the world. In addition, promising product launches, an increase in awareness regarding available treatment options for anaphylaxis among healthcare professionals and patients are boosting the market revenue growth of fatal anaphylaxis treatment market. However, the cost of the treatment, lack of awareness in underdeveloped regions regarding the allergic reaction treatment, and side effects of the drugs used for treatment are hindering the growth of fatal anaphylaxis treatment market.

The global Anaphylaxis treatment market has been categorized into-

  1. Drug class
  • Adrenergic Agents (Epinephrine)
  • Anti-Histamines
  • Others
  1. Route of administration
  • Parenteral
  • Oral
  • Others
  1. End-users
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

And lastly on the basis of geographical regions, the global Anaphylaxis treatment market has been segmented into following regions- North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America expected to lead the fatal anaphylaxis treatment market due to increase in the incidence of anaphylaxis, lifestyle changes and raising awareness about available treatment for anaphylaxis among healthcare professionals. Europe anaphylaxis treatment market expected to grow at healthier rate due to increased adoption of the new technologies in the treatment of anaphylaxis. Asia Pacific anaphylaxis treatment market expected to grow at faster rates owing to larger pool patients coupled with high medical unmet need in the region.

Some of the market players in Anaphylaxis treatment market are ALK-Abelló (Denmark), Lincoln Medical Ltd. (New Zealand), Mylan NV ( U.S.), Adamis Pharmaceutical Corporation (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline Plc. (U.K) , Merck & Co., Inc. (U.S.) to name a few. In 2017, U.S.FDA approved Adamis Pharmaceutical’s epinephrine injection, “symjepi” (0.3mg/ml) for the emergency treatment of allergic reactions, including anaphylaxis.

Global Anaphylaxis treatment market is much consolidated in nature due to the presence of very few players in the market. The introduction of the auto-injectors to treat the anaphylaxis revolutionized the anaphylaxis treatment market. Market players are increasing their market presence by collaborations and partnerships. In addition, marketers focusing on the product launches and expanding into other regions for better revenue realization. For instance, in 2015, the long-term partnership agreement grants bioCSL exclusive rights in Australia and New Zealand to ALK’s sublingual allergy immunotherapy tablets (SLIT-tablets) for house dust mite (HDM) allergy and grass pollen allergy (marketed as GRAZAX in Europe and GRASTEK in North America), and its adrenaline auto-injector, Jext. Companies reducing the costs by introducing the generic, cheaper versions of the epinephrine auto-injectors to penetrate into the market. For instance, Mylan N.V. has introduced the generic version of EpiPen at half the price.

 

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX